University of California Los Angeles (UCLA) - Santa Monica Cancer Care
Welcome,         Profile    Billing    Logout  
 22 Trials 
27 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chawla, Sant
TANGENT, NCT05417789: Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

Recruiting
3
128
Europe, Canada, US, RoW
Emactuzumab, Placebo
SynOx Therapeutics Limited
TGCT
04/26
09/27
INVINCIBLE-3, NCT06263231: A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults with Soft Tissue Sarcomas

Recruiting
3
333
Europe, Canada, US
INT230-6, Eribulin, Trabectedin, Pazopanib
Intensity Therapeutics, Inc., Premier Research Group plc
Sarcoma,Soft Tissue
12/27
12/28
SUNRISELMS, NCT05269355 / 2022-000073-12: A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

Active, not recruiting
2/3
360
Europe, Canada, US, RoW
Unesbulin, PTC596, Dacarbazine, DTIC, Placebo
PTC Therapeutics, PTC Therapeutics, Inc.
Leiomyosarcoma
06/24
06/24
RINGSIDE, NCT04871282 / 2020-005833-34: A Study of AL102 in Patients With Progressing Desmoid Tumors

Active, not recruiting
2/3
192
Europe, US, RoW
AL102, Placebo
Immunome, Inc.
Desmoid, Desmoid Tumor
10/25
10/26
HopES, NCT03778996: SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma

Active, not recruiting
2
31
US
Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS), SM-88
Sarcoma Oncology Research Center, LLC, Tyme, Inc
Sarcoma, Ewing, Sarcoma
12/24
03/25
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
FIBROSARC USA, NCT03420014: Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients

Recruiting
2
114
US
Doxorubicin, L19TNF plus doxorubicin
Philogen S.p.A.
Leiomyosarcoma
12/24
12/25
CHS-388-202, NCT06679985: A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

Recruiting
2
72
US
Casdozokitug, CHS-388, Toripalimab, Bevacizumab
Coherus Biosciences, Inc.
Hepatocellular Carcinoma
09/27
09/27
NCT04486781: A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma

Recruiting
2
38
US
Pembrolizumab + sEphB4-HSA
Vasgene Therapeutics, Inc
Metastatic Urothelial Carcinoma
12/25
12/25
NCT05448820: YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

Active, not recruiting
1/2
15
US
YH001, Envafolimab, KN035, Doxorubicin
Tracon Pharmaceuticals Inc.
Advanced Sarcoma, Metastatic Sarcoma, Soft Tissue Sarcoma
11/23
09/25
Keynote MK-3475-B66, NCT03611868: A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Recruiting
1/2
230
US, RoW
Phase 1b: APG-115+pembrolizumab, KEYTRUDA®
Ascentage Pharma Group Inc., Merck Sharp & Dohme LLC
Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST)
12/24
03/25
SAINT, NCT03138161: Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma

Recruiting
1/2
45
US
Trabectedin, Yondelis, Ipilimumab, Yervoy, Nivolumab, Opdivo
Sarcoma Oncology Research Center, LLC, Bristol-Myers Squibb
Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma
12/24
03/25
NCT04165330: Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

Active, not recruiting
1/2
56
US
AL3818, Anlotinib hydrochloride, Nivolumab Injection, Opdivo
Sarcoma Oncology Research Center, LLC, Advenchen Laboratories, LLC
Solid Tumor, Adult, Soft Tissue Sarcoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer
12/24
03/25
NCT04887298: Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases

Completed
1/2
36
US
Liposomal Annamycin (L-Annamycin)
Moleculin Biotech, Inc.
Sarcoma,Soft Tissue, Pulmonary Metastasis
09/22
08/24
NCT06471673: A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

Recruiting
1/2
18
US
BC1 cell line, Bria-OTS regimen and CPI (tislelizumab), Bria-OTS regimen and CPI (tislelizumab) expansion cohort
BriaCell Therapeutics Corporation
Breast Cancer, Breast Tumor, Cancer of Breast, Cancer of the Breast, Malignant Tumor of Breast, Tumors, Breast
04/25
10/25
NCT05756907: Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer

Recruiting
1/2
165
US, RoW
SON-1010
Sonnet BioTherapeutics, Hoffmann-La Roche
Advanced Solid Tumor, Platinum-resistant Ovarian Cancer
06/24
05/25
ARDOXSO, NCT04798716: The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19

Not yet recruiting
1/2
55
US
MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8), Ardoxso, MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8), MSC-exosomes delivered intravenously every other day (8:8:8)
AVEM HealthCare
Covid19, Novel Coronavirus Pneumonia, Acute Respiratory Distress Syndrome
09/24
12/24
IMM1104-101, NCT05585320: A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

Hourglass Nov 2024 - Dec 2024 : Initial data from at least one additional arm of the Phase 2a portion
Recruiting
1/2
210
US
IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104, IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + mGnP, IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + mFFX
Immuneering Corporation
Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
06/26
06/27
SALA-002-EW16, NCT03600649: Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Active, not recruiting
1
50
US
Seclidemstat, LSD1 Inhibitor, SP-2577, Cyclophosphamide, Topotecan
Salarius Pharmaceuticals, LLC, National Pediatric Cancer Foundation
Ewing Sarcoma, Myxoid Liposarcoma, Sarcoma,Soft Tissue, Desmoplastic Small Round Cell Tumor, Extraskeletal Myxoid Chondrosarcoma, Angiomatoid Fibrous Histiocytoma, Clear Cell Sarcoma, Primary Pulmonary Myxoid Sarcoma, Myoepithelial Tumor, Sclerosing Epithelioid Fibrosarcoma, Fibromyxoid Tumor
09/25
12/25
NCT04762602: A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations

Active, not recruiting
1
90
Europe, US
HMPL-306
Hutchmed
Isocitrate Dehydrogenase Gene Mutation
03/25
09/25
NCT04221204: A Monotherapy in Subjects With Advanced Solid Tumors

Active, not recruiting
1
42
US, RoW
Highly selective FGFR1-3 inhibitor
3D Medicines (Beijing) Co., Ltd.
Solid Tumor, Adult
12/24
12/24
NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting
1
321
Europe, US
INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide
Inhibrx Biosciences, Inc
Colorectal Adenocarcinoma, Ewing Sarcoma
06/26
12/26
NCT05990920: Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy

Completed
1
6
US
SNK02
NKGen Biotech, Inc.
Pathologically Confirmed Cancer Refractory to Conventional Therapy, Refractory Cancer, Metastatic Cancer, Recurrent Cancer, Solid Tumor, Adult, Solid Tumor, Advanced Cancer, Advanced Solid Tumor
04/24
04/24
CFT8634-1101, NCT05355753: A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

Terminated
1
49
US
CFT8634
C4 Therapeutics, Inc.
Synovial Sarcoma, Soft Tissue Sarcoma
12/23
12/23
HBI-2376-101, NCT05163028: A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

Recruiting
1
42
US
HBI-2376
HUYABIO International, LLC.
Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
12/24
12/24
NCT05485974: A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

Recruiting
1
44
US
HBI-2438
HUYABIO International, LLC.
Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas, Colon Cancer, Solid Tumor, Cancer
08/25
08/25
DF6215-001, NCT06108479: Study of DF6215 in Patients With Advanced Solid Tumors

Recruiting
1
102
Europe, US, RoW
DF6215
Dragonfly Therapeutics
Solid Tumor, Adult
09/25
12/27

Download Options